HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sho-ichi Yamagishi Selected Research

Diabetic Angiopathies (Diabetic Angiopathy)

1/2015Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications.
8/2013Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor.
5/2012Advanced glycation end products increase permeability of brain microvascular endothelial cells through reactive oxygen species-induced vascular endothelial growth factor expression.
9/2010Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice.
12/2009Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications.
1/2009Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease.
1/2008Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications.
1/2008Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease.
1/2008Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation.
1/2008Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sho-ichi Yamagishi Research Topics

Disease

33Atherosclerosis
03/2015 - 09/2002
24Diabetic Nephropathies (Diabetic Nephropathy)
04/2016 - 06/2002
22Diabetic Retinopathy (Retinopathy, Diabetic)
01/2013 - 01/2002
20Inflammation (Inflammations)
02/2015 - 01/2005
19Diabetic Angiopathies (Diabetic Angiopathy)
01/2015 - 02/2004
19Cardiovascular Diseases (Cardiovascular Disease)
12/2014 - 01/2006
17Type 2 Diabetes Mellitus (MODY)
01/2014 - 03/2007
16Insulin Resistance
01/2015 - 01/2005
12Chronic Renal Insufficiency
12/2013 - 08/2006
11Proteinuria
09/2012 - 01/2009
10Hyperglycemia
04/2016 - 01/2005
9Diabetes Mellitus
11/2013 - 10/2002
9Hypertension (High Blood Pressure)
03/2013 - 01/2006
8Neoplasms (Cancer)
02/2015 - 02/2004
7Body Weight (Weight, Body)
04/2016 - 05/2003
7Non-alcoholic Fatty Liver Disease
11/2015 - 07/2010
7Vascular System Injuries
03/2015 - 08/2006
7Coronary Artery Disease (Coronary Atherosclerosis)
03/2015 - 01/2006
6Alzheimer Disease (Alzheimer's Disease)
04/2011 - 06/2002
5Fibrosis (Cirrhosis)
02/2015 - 05/2007
5Neoplasm Metastasis (Metastasis)
02/2015 - 02/2004
5Melanoma (Melanoma, Malignant)
04/2014 - 02/2004
5Glucose Intolerance
11/2013 - 05/2007
5Metabolic Syndrome (Dysmetabolic Syndrome X)
08/2010 - 04/2007
4Hypoglycemia (Reactive Hypoglycemia)
04/2016 - 12/2012
4Hepatocellular Carcinoma (Hepatoma)
11/2015 - 05/2006
4Atherosclerotic Plaque (Atheroma)
12/2014 - 04/2007
4Chronic Kidney Failure (Chronic Renal Failure)
10/2014 - 07/2006
4Necrosis
01/2013 - 02/2008
4Dehydration (Water Stress)
12/2012 - 10/2007
4Essential Hypertension
01/2011 - 05/2006
4Dyslipidemias (Dyslipidemia)
09/2010 - 12/2009
3Liver Diseases (Liver Disease)
02/2015 - 01/2008
3Acute Coronary Syndrome
01/2013 - 01/2006
3Hyperlipidemias (Hyperlipidemia)
12/2012 - 03/2007
3Hypercholesterolemia
02/2011 - 01/2006
3Eye Diseases (Eye Disease)
01/2008 - 05/2003

Drug/Important Bio-Agent (IBA)

88Advanced Glycation End ProductsIBA
11/2015 - 06/2002
32pigment epithelium-derived factorIBA
03/2015 - 08/2002
22Receptor for Advanced Glycation End ProductsIBA
04/2015 - 02/2004
21Proteins (Proteins, Gene)FDA Link
02/2015 - 06/2002
18Biomarkers (Surrogate Marker)IBA
04/2015 - 01/2007
14Glucose (Dextrose)FDA LinkGeneric
04/2016 - 01/2005
12Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2014 - 01/2002
11N,N-dimethylarginine (asymmetric dimethylarginine)IBA
03/2014 - 08/2006
8LigandsIBA
02/2015 - 10/2007
8Reactive Oxygen Species (Oxygen Radicals)IBA
02/2013 - 01/2005
7Insulin (Novolin)FDA Link
04/2016 - 01/2008
7GlyceraldehydeIBA
04/2015 - 12/2002
7CreatinineIBA
12/2013 - 01/2009
7HDL CholesterolIBA
10/2013 - 04/2007
7Telmisartan (Micardis)FDA Link
07/2013 - 01/2006
7Atorvastatin (Lipitor)FDA Link
01/2013 - 01/2006
6LipidsIBA
05/2015 - 04/2007
6Angiotensin IIIBA
05/2011 - 10/2002
6Glycoproteins (Glycoprotein)IBA
03/2011 - 07/2007
5AlbuminsIBA
05/2015 - 01/2010
5Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
03/2015 - 01/2006
5LDL CholesterolIBA
12/2014 - 06/2007
5oxidized low density lipoproteinIBA
12/2014 - 05/2006
5C-Reactive ProteinIBA
12/2014 - 05/2006
5Nitric Oxide Synthase (NO Synthase)IBA
03/2014 - 06/2009
5NADPH Oxidases (NAD(P)H oxidase)IBA
02/2013 - 06/2007
5Triglycerides (Triacylglycerol)IBA
06/2012 - 09/2009
5LDL Lipoproteins (beta Lipoproteins)IBA
03/2012 - 05/2006
5PPAR gammaIBA
07/2010 - 01/2008
4Blood Glucose (Blood Sugar)IBA
05/2015 - 09/2010
4Nucleotide AptamersIBA
04/2014 - 07/2007
4Nitric Oxide (Nitrogen Monoxide)FDA Link
03/2014 - 01/2008
4CholesterolIBA
12/2013 - 12/2009
4Pioglitazone (Actos)FDA Link
11/2013 - 02/2010
4Glucagon-Like Peptide 1 (GLP 1)IBA
01/2013 - 09/2011
4Peptides (Polypeptides)IBA
12/2012 - 03/2010
4Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
09/2011 - 05/2007
4Nifedipine (Adalat)FDA LinkGeneric
07/2010 - 01/2006
4Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
09/2009 - 05/2004
4Angiotensin II Type 1 Receptor BlockersIBA
01/2008 - 10/2002
4Retinaldehyde (Retinal)IBA
07/2007 - 01/2002
3Uric Acid (Urate)IBA
04/2016 - 07/2010
38-Hydroxy-2'-DeoxyguanosineIBA
05/2015 - 12/2009
3Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
05/2015 - 07/2006
3EnzymesIBA
04/2015 - 06/2009
3glimepiride (Amarel)FDA LinkGeneric
01/2014 - 10/2013
3Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
03/2013 - 06/2011
3Aspartate Aminotransferases (Aspartate Transaminase)IBA
12/2012 - 06/2012
3AdiponectinIBA
07/2012 - 02/2008
3Fatty Acid-Binding ProteinsIBA
06/2011 - 12/2009
3Amlodipine (Norvasc)FDA LinkGeneric
06/2011 - 09/2010
3HMGB1 Protein (HMG1)IBA
06/2011 - 12/2009
3Anti-Inflammatory Agents (Anti-Inflammatories)IBA
07/2010 - 01/2008
3Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
08/2007 - 01/2005
3CytokinesIBA
08/2007 - 01/2005
23-nitrotyrosineIBA
05/2015 - 06/2007
2Carnitine (L-Carnitine)FDA LinkGeneric
03/2015 - 12/2014
2Amyloid (Amyloid Fibrils)IBA
02/2015 - 01/2008

Therapy/Procedure

15Therapeutics
03/2015 - 02/2004
4Renal Dialysis (Hemodialysis)
03/2015 - 04/2013
3Light Coagulation
03/2011 - 03/2007
3Drug Therapy (Chemotherapy)
01/2008 - 06/2005
2Percutaneous Coronary Intervention
03/2015 - 01/2011